Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Subscribe To Our Newsletter & Stay Updated
